Its very likely that every drug plan has already identified those two drugs in every class so its not necessary to add Wegovy from a compliance perspective
It should be noted that MTC is rare (estimated incidence of 0.2 cases per 100,000 patient-years), and as such, it is very difficult to definitively rule out an association between GLP-1RA and thyroid malignancies
This has accelerated interest in combining GLP-1 RA therapy with agents that attenuate skeletal muscle catabolism: myostatin/activin inhibitors, selective androgen receptor modulators, and triple agonists such as retatrutide that include glucagon receptor activation
6 Tirzepatide has an additional GIP receptor agonist function that can lead to a different side-effect profile
In these cases, the conservative approach becomes even more important
It activates the GLP-1 receptor, which signals the pancreas to release insulin, slows gastric emptying, and reduces appetite.nnThree engineered changes to the native GLP-1 backbone (an Aib substitution at position 8, a Lys-to-Arg substitution at position 34, and a C18 fatty diacid attached at lysine 26) give semaglutide its long plasma half-life and once-weekly dosing profile